药物涂层球囊与药物洗脱支架治疗小冠状动脉病变的长期疗效与安全性(BASKET-SMALL 2):随机非劣效试验3年随访
BASKET-SMALL 2试验预设长期随访,在德国、瑞士、奥地利14个中心纳入758例冠状动脉<3 mm原发病变且需PCI的患者,1:1随机接受药物涂层球囊或第二代药物洗脱支架,随访3年。主要终点主要不良心脏事件(心源性死亡、非致死性心肌梗死、靶血管血运重建)Kaplan-Meier估计两组均为15%(HR 0.99,95%CI 0.68-1.45;P=0.95)。全因死亡、非致死性心肌梗死、靶血管血运重建、支架内血栓及大出血两组均无显著差异。结论认为药物涂层球囊与药物洗脱支架在小血管原发病变中疗效与安全性维持至3年。
要点
- 小血管原发病变PCI患者3年主要不良心脏事件:药物涂层球囊组与药物洗脱支架组Kaplan-Meier估计均为15%(HR 0.99,95%CI 0.68-1.45;P=0.95)。
- 心源性死亡药物涂层球囊组5% vs 药物洗脱支架组4%(HR 1.29,95%CI 0.63-2.66;P=0.49),无显著差异。
- 靶血管血运重建两组Kaplan-Meier估计均为9%(HR 0.95,95%CI 0.58-1.56;P=0.83)。
- 支架内血栓药物涂层球囊组1% vs 药物洗脱支架组2%(HR 0.33,95%CI 0.07-1.64;P=0.18),大出血2% vs 4%(HR 0.43,95%CI 0.17-1.13;P=0.088),均未达统计学显著。
- 稳定症状患者双联抗血小板治疗推荐药物涂层球囊后1个月、药物洗脱支架后6个月;急性冠脉综合征患者均12个月。
适用人群与场景
- 14个中心(德国、瑞士、奥地利)纳入的冠状动脉<3 mm原发病变且需经皮冠状动脉介入治疗的患者,全人群设计。
- 稳定症状患者双联抗血小板治疗:药物涂层球囊后1个月,药物洗脱支架后6个月;急性冠脉综合征患者均为12个月。
处置流程与药物剂量
- 双联抗血小板治疗推荐:稳定症状患者药物涂层球囊后1个月、药物洗脱支架后6个月;急性冠脉综合征患者均12个月。
研究设计与关键结果
- 多中心、随机、开放标签、非劣效试验预设长期随访,14个中心,758例患者随机接受药物涂层球囊(n=382)或第二代药物洗脱支架(n=376),随访3年。
- 主要终点主要不良心脏事件(心源性死亡、非致死性心肌梗死、靶血管血运重建)Kaplan-Meier估计两组均为15%(HR 0.99,95%CI 0.68-1.45;P=0.95)。
- 心源性死亡药物涂层球囊组5% vs 药物洗脱支架组4%(HR 1.29,95%CI 0.63-2.66;P=0.49);非致死性心肌梗死两组均为6%(HR 0.82,95%CI 0.45-1.51;P=0.52);靶血管血运重建两组均为9%(HR 0.95,95%CI 0.58-1.56;P=0.83)。
- 全因死亡两组Kaplan-Meier估计均为8%(HR 1.05,95%CI 0.62-1.77;P=0.87)。
- 支架内血栓药物涂层球囊组1% vs 药物洗脱支架组2%(HR 0.33,95%CI 0.07-1.64;P=0.18);大出血(BARC 3-5型)药物涂层球囊组2% vs 药物洗脱支架组4%(HR 0.43,95%CI 0.17-1.13;P=0.088),均未达统计学显著。
证据类型、等级与局限
- 证据类型:多中心、随机、开放标签、非劣效试验的预设长期随访(BASKET-SMALL 2),按改良意向性治疗原则全分析集分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在小血管原发病变PCI中,药物涂层球囊与第二代药物洗脱支架3年主要不良心脏事件相当,支持药物涂层球囊作为该人群的替代选择。
- 双联抗血小板治疗疗程按原文推荐:稳定症状患者药物涂层球囊后1个月、药物洗脱支架后6个月;急性冠脉综合征患者均12个月。
指南或共识出处
- BASKET-SMALL 2试验(NCT01574534),发表于Lancet。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In the treatment of de-novo coronary small vessel disease, drug-coated balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up to 12 months, but data beyond 1 year is sparse. We aimed to test the long-term efficacy and safety of DCBs regarding clinical endpoints in an all-comer population undergoing percutaneous coronary intervention.
METHODS: In this prespecified long-term follow-up of a multicentre, randomised, open-label, non-inferiority trial, patients from 14 clinical sites in Germany, Switzerland, and Austria with de-novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention were randomly assigned 1:1 to DCB or second-generation DES and followed over 3 years for major adverse cardiac events (ie, cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation [TVR]), all-cause death, probable or definite stent thrombosis, and major bleeding (Bleeding Academic Research Consortium bleeding type 3-5). Analyses were performed on the full analysis set according to the modified intention-to-treat principle. Dual antiplatelet therapy was recommended for 1 month after DCB and 6 months after DES with stable symptoms, but 12 months with acute coronary syndromes. The study is registered with ClinicalTrials.gov, NCT01574534 and is ongoing.
FINDINGS: Between April 10, 2012, and Feb 1, 2017, of 883 patients assessed, 758 (86%) patients were randomly assigned to the DCB group (n=382) or the DES group (n=376). The Kaplan-Meier estimate of the rate of major adverse cardiac events was 15% in both the DCB and DES groups (hazard ratio [HR] 0·99, 95% CI 0·68-1·45; p=0·95). The two groups were also very similar concerning the single components of adverse cardiac events: cardiac death (Kaplan-Meier estimate 5% vs 4%, HR 1·29, 95% CI 0·63-2·66; p=0·49), non-fatal myocardial infarction (both Kaplan-Meier estimate 6%, HR 0·82, 95% CI 0·45-1·51; p=0·52), and TVR (both Kaplan-Meier estimate 9%, HR 0·95, 95% CI 0·58-1·56; p=0·83). Rates of all-cause death were very similar in DCB versus DES patients (both Kaplan-Meier estimate 8%, HR 1·05, 95% CI 0·62-1·77; p=0·87). Rates of probable or definite stent thrombosis (Kaplan-Meier estimate 1% vs 2%; HR 0·33, 95% CI 0·07-1·64; p=0·18) and major bleeding (Kaplan-Meier estimate 2% vs 4%, HR 0·43, 95% CI 0·17-1·13; p=0·088) were numerically lower in DCB versus DES, however without reaching significance.
INTERPRETATION: There is maintained efficacy and safety of DCB versus DES in the treatment of de-novo coronary small vessel disease up to 3 years.
FUNDING: Swiss National Science Foundation, Basel Cardiovascular Research Foundation, and B Braun Medical.
参考来源
- Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020. PMID: 33091360. doi:10.1016/S0140-6736(20)32173-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。